Back to Agenda
Session 1: Setting up the Scene: More than 10 Years of ATMPs in Europe
Session Chair(s)
Jacquelyn Awigena-Cook, MSc
Director, Global Regulatory Policy & Intelligence
Bristol Myers Squibb, United Kingdom
Topics covered in this session include:
- The inclusion of Innovation Therapies in the Pharma Strategy
- The last 10 years of Innovative Therapies in the EU
- Complexities in cell and gene therapies development: how have we accommodated them in our reimbursement systems.
Speaker(s)
Reflections from the Various Stakeholders
Emil Andrei Cochino, MD, MHS
European Medicines Agency, Netherlands
Scientific Senior Specialist (Risk Management)
Anne Kerber
Bristol Myers Squibb , Germany
SVP Head of Cell Therapy Development
Antonella Cardone
Cancer Patients Europe, Belgium
Director
François Houyez
European Organisation for Rare Diseases (EURORDIS), France
Treatment Information and Access Director, Health Policy Advisor
Have an account?